Senescence and the Early Ageing Phenotype After Chemotherapy for Testicular Cancer: the SEA-CAT Study

Launched by UNIVERSITY MEDICAL CENTER GRONINGEN · Oct 1, 2019

Keywords

ClinConnect Summary

The SEA-CAT Study is looking into how chemotherapy for testicular cancer affects the body over time, particularly focusing on a process called "cellular senescence," which is when cells stop dividing and can lead to inflammation and an early aging appearance. Researchers believe that the chemotherapy drugs used, especially cisplatin, may cause damage not only to cancer cells but also to healthy cells, which could contribute to long-term side effects and changes in health as survivors age.

To participate in this study, men who were diagnosed with metastatic testicular cancer (stage II or higher) between 1999 and 2012 and received cisplatin-based chemotherapy before turning 50 may be eligible. Additionally, men who are about to start cisplatin chemotherapy or those diagnosed with early-stage (stage I) testicular cancer under the age of 50 can also join. Participants can expect to contribute to understanding the long-term effects of their treatment, which may help improve care for future patients. It's important to note that individuals who cannot provide clear consent, such as those with certain mental health conditions, will not be included in the study.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• In order to be eligible to participate in the cross-sectional part of this study, a subject must meet all of the following criteria:
• • Diagnosed with metastatic testicular cancer in 1999-2012 (stage II or higher)
• • Received first-line cisplatin-based chemotherapy
• • Was younger than 50 years of age at start of chemotherapy
• In order to be eligible to participate in the longitudinal part of this study, a subject must meet all of the following criteria:
• Chemotherapy-group:
• • Diagnosis of metastatic testicular cancer (stage II or higher)
• • Is about to start with first-line cisplatin-based chemotherapy
• • Younger than 50 years of age at diagnosis of metastatic testicular cancer
• Stage I control-group:
• • Diagnosis of testicular cancer stage I disease
• • Younger than 50 years of age at diagnosis of testicular cancer
• Exclusion Criteria:
• A potential subject who meets any of the following criteria will be excluded from participation in this study:
• • - Not able to provide informed consent (in example in case of mental or psychiatric disability)